Business Context and Reporting Period
This Form 8-K was filed by Catalyst Biosciences, Inc. (CBIO) on April 16, 2021. The company is a Delaware corporation focused on discovery research in complement and protease medicines. The report details the entry into a material definitive agreement regarding laboratory facilities.
Key Financial Metrics
This filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed relates to the new lease agreement:
- License Fee: $104,000 per month.
Material Changes
The material change reported is the execution of a License Agreement with SL 2T, LLC ("SmartLabs") for laboratory space at Two Tower Place in South San Francisco, California. This agreement is intended to support the company's ongoing research efforts.
Outlook, Risks, and Unusual Items
Agreement Terms:
- Term: Commences May 1, 2021, and expires April 30, 2022.
- Extension Option: Catalyst has an option to extend the term for an additional six-month period.
- Termination: SmartLabs retains the right to terminate for "cause" if Catalyst breaches the agreement and fails to cure the breach within five days of written notice.
Documentation: The full text of the agreement will be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ending June 30, 2021.
Investor Verification Checklist
- Verify the total annualized cost of the new facility ($104,000 x 12 months) against the company's current cash runway.
- Review the upcoming Form 10-Q (due after June 30, 2021) for the full text of the Lease Agreement and any additional covenants.
- Confirm whether the company has exercised or plans to exercise the six-month extension option.
- Assess the impact of this new fixed operating expense on the company's burn rate.